Eric Van Belle

Eric Van Belle

Auto-generated profile, based on publicly available information

Eric Van Belle

Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Heart Journal
Verified
Journal Article
Closed access
CVChristiaan Vrints
Christiaan Vrints
FAFelicita Andreotti
Felicita Andreotti
KKKonstantinos C Koskinas
Konstantinos C Koskinas
XRXavier Rossello
Xavier Rossello
MAMarianna Adamo
Marianna Adamo
ASAleksandr Borisovich Shek
Aleksandr Borisovich Shek

3 May 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MGMartine Gilard
Martine Gilard
HEHélène Eltchaninoff
Hélène Eltchaninoff
BIBernard Iung
Bernard Iung
PDPatrick Donzeau-Gouge
Patrick Donzeau-Gouge
KCKarine Chevreul
Karine Chevreul
FIFRANCE 2 Investigators
FRANCE 2 Investigators
Transcatheter aortic-valve implantation (TAVI) is an emerging intervention for the treatment of high-risk patients with severe aortic stenosis and coexisting illnesses. We report the results of a prospective multicenter study of the French national transcatheter aortic-valve implantation registry, FRANCE 2. All TAVIs performed in France, as listed in the FRANCE 2 registry, were prospectively included in the study. The primary end point was death from any cause. A total of 3195 patients were enrolled between January 2010 and October 2011 at 34 centers. The mean (±SD) age was 82.7±7.2 years; 49% of the patients were women. All patients were highly symptomatic and were at high surgical risk for aortic-valve replacement. Edwards SAPIEN and Medtronic CoreValve devices were implanted in 66.9% and 33.1% of patients, respectively. Approaches were either transarterial (transfemoral, 74.6%; subclavian, 5.8%; and other, 1.8%) or transapical (17.8%). The procedural success rate was 96.9%. Rates of death at 30 days and 1 year were 9.7% and 24.0%, respectively. At 1 year, the incidence of stroke was 4.1%, and the incidence of periprosthetic aortic regurgitation was 64.5%. In a multivariate model, a higher logistic risk score on the European System for Cardiac Operative Risk Evaluation (EuroSCORE), New York Heart Association functional class III or IV symptoms, the use of a transapical TAVI approach, and a higher amount of periprosthetic regurgitation were significantly associated with reduced survival. This prospective registry study reflected real-life TAVI experience in high-risk elderly patients with aortic stenosis, in whom TAVI appeared to be a reasonable option. (Funded by Edwards Lifesciences and Medtronic.)

11 May 2017 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JDJustin E. Davies
Justin E. Davies
SSSayan Sen
Sayan Sen
HDHakim-Moulay Dehbi
Hakim-Moulay Dehbi
RARasha Al-Lamee
Rasha Al-Lamee
RPRicardo Petraco
Ricardo Petraco
JEJavier Escaned
Javier Escaned
Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR. We randomly assigned 2492 patients with coronary artery disease, in a 1:1 ratio, to undergo either iFR-guided or FFR-guided coronary revascularization. The primary end point was the 1-year risk of major adverse cardiac events, which were a composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization. The trial was designed to show the noninferiority of iFR to FFR, with a margin of 3.4 percentage points for the difference in risk. At 1 year, the primary end point had occurred in 78 of 1148 patients (6.8%) in the iFR group and in 83 of 1182 patients (7.0%) in the FFR group (difference in risk, −0.2 percentage points; 95% confidence interval [CI], −2.3 to 1.8; P<0.001 for noninferiority; hazard ratio, 0.95; 95% CI, 0.68 to 1.33; P=0.78). The risk of each component of the primary end point and of death from cardiovascular or noncardiovascular causes did not differ significantly between the groups. The number of patients who had adverse procedural symptoms and clinical signs was significantly lower in the iFR group than in the FFR group (39 patients [3.1%] vs. 385 patients [30.8%], P<0.001), and the median procedural time was significantly shorter (40.5 minutes vs. 45.0 minutes, P=0.001). Coronary revascularization guided by iFR was noninferior to revascularization guided by FFR with respect to the risk of major adverse cardiac events at 1 year. The rate of adverse procedural signs and symptoms was lower and the procedural time was shorter with iFR than with FFR. (Funded by Philips Volcano; DEFINE-FLAIR ClinicalTrials.gov number, NCT02053038.)

29 November 2012 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JCJean-Philippe Collet
Jean-Philippe Collet
TCThomas Cuisset
Thomas Cuisset
GRGrégoire Rangé
Grégoire Rangé
GCGuillaume Cayla
Guillaume Cayla
SESimon Elhadad
Simon Elhadad
GMGilles Montalescot
Gilles Montalescot
Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy.

1 October 2014 in JACC
Verified
Journal Article
Open access
NJNils P. Johnson
Nils P. Johnson
Toth-Gayor GaborToth-Gayor Gabor
Toth-Gayor Gabor
DLDejian Lai
Dejian Lai
HZHongjian Zhu
Hongjian Zhu
GAGöksel Açar
Göksel Açar
KGK. Lance Gould
K. Lance Gould
Fractional flow reserve (FFR) has become an established tool for guiding treatment, but its graded relationship to clinical outcomes as modulated by medical therapy versus revascularization remains unclear. The study hypothesized that FFR displays a continuous relationship between its numeric value and prognosis, such that lower FFR values confer a higher risk and therefore receive larger absolute benefits from revascularization. Meta-analysis of study- and patient-level data investigated prognosis after FFR measurement. An interaction term between FFR and revascularization status allowed for an outcomes-based threshold. A total of 9,173 (study-level) and 6,961 (patient-level) lesions were included with a median follow-up of 16 and 14 months, respectively. Clinical events increased as FFR decreased, and revascularization showed larger net benefit for lower baseline FFR values. Outcomes-derived FFR thresholds generally occurred around the range 0.75 to 0.80, although limited due to confounding by indication. FFR measured immediately after stenting also showed an inverse relationship with prognosis (hazard ratio: 0.86, 95% confidence interval: 0.80 to 0.93; p < 0.001). An FFR-assisted strategy led to revascularization roughly half as often as an anatomy-based strategy, but with 20% fewer adverse events and 10% better angina relief. FFR demonstrates a continuous and independent relationship with subsequent outcomes, modulated by medical therapy versus revascularization. Lesions with lower FFR values receive larger absolute benefits from revascularization. Measurement of FFR immediately after stenting also shows an inverse gradient of risk, likely from residual diffuse disease. An FFR-guided revascularization strategy significantly reduces events and increases freedom from angina with fewer procedures than an anatomy-based strategy.

27 August 2018 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
MSMiguel Sousa-Uva
Miguel Sousa-Uva
FNFranz-Josef Neumann
Franz-Josef Neumann
AAAnders Ahlsson
Anders Ahlsson
FAFernando Alfonso
Fernando Alfonso
ABAdrian P. Banning
Adrian P. Banning
RHRobert Henderson
Robert Henderson